Skip to main content
Lydia Visser

My research in the Pathology department is mainly focused on immunological aspects of B-cell lymphoma. I study interactions of tumor cells with the microenvironment, and signaling pathways in Hodgkin lymphoma and non-Hodgkin lymphomas.

Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitro
Published in: PLoS ONE
BACKGROUND AND PURPOSE: PARP inhibitors have been shown to increase the efficacy of radiotherapy in preclinical models. Radioimmunotherapy results in selective radiation cytotoxicity of targeted tumour cells. Here we investigate the combined effect of anti-CD37 β-emitting 177Lu-NNV003 radioimmunotherapy and the PARP inhibitor olaparib, and gene expression profiles in CD37 positive non-Hodgkin’s lymphoma cell lines. MATERIALS AND METHODS: The combined effect of 177Lu-NNV003 and olaparib was studied in seven cell lines using a fixed-ratio ray design, and combination index was calculated for each combination concentration. mRNA was extracted before...
Marion M Malenge, Astri Fjelde Maaland, Ada Repetto-Llamazares, Brian Middleton, Marcel Nijland, Lydia Visser, Sebastian Patzke, Helen Heyerdahl, Arne Kolstad, Trond Stokke, Anne Hansen Ree, Jostein Dahle
Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma
Published in: Blood cancer journal
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype. Despite the proven efficacy of combined immunochemotherapy (R-CHOP) in the majority of patients, ~40% of DLBCL patients do not respond or will relapse and consequently have a very poor prognosis. The development of targeted therapies has not improved patient survival, underscoring the need for new treatment approaches. Using an unbiased genome-wide CD20 guilt-by-association approach in more than 1800 DLBCL patients, we previously identified the estrogen receptor beta (ERβ) as a new target in DLBCL. Here, we demonstrate...
Myra Langendonk, Mathilde R W de Jong, Nienke Smit, Jonas Seiler, Bart Reitsma, Emanuele Ammatuna, Andor W J M Glaudemans, Anke van den Berg, Gerwin A Huls, Lydia Visser, Tom van Meerten
A gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma
Published in: Blood
Classical Hodgkin lymphoma (cHL) is a common malignancy in children and adolescents. Although cHL is highly curable, treatment with chemotherapy and radiation often come at the cost of long-term toxicity and morbidity. Effective risk-stratification tools are needed to tailor therapy. Here, we used gene expression profiling (GEP) to investigate tumor microenvironment (TME) biology, to determine molecular correlates of treatment failure, and to develop an outcome model prognostic for pediatric cHL. A total of 246 formalinfixed, paraffin-embedded tissue biopsies from patients enrolled in the Children’s Oncology Group trial AHOD0031...
Rebecca L. Johnston, Anja Mottok, Fong Chun Chan, Aixiang Jiang, Arjan Diepstra, Lydia Visser, Adele Telenius, Randy D. Gascoyne, Debra L. Friedman, Cindy L. Schwartz, Kara M. Kelly, David W. Scott, Terzah M. Horton, Christian Steidl
Computational study, synthesis and evaluation of active peptides derived from Parasporin-2 and spike protein from Alphacoronavirus against colon cancer cells
Published in: Bioscience reports
Parasporin-2Aa1 (PS2Aa1) is a toxic protein of 37 KDa (30 KDa, activated form produced by proteolysis) that was shown to be cytotoxic against specific human cancer cells, although its mechanism of action has not been elucidated yet. In order to study the role of some native peptide fragments of proteins on anticancer activity, here we investigated the cytotoxic effect of peptide fragments from domain-1 of PS2Aa1 and one of the loops present in the binding region of the virus spike protein from Alphacoronavirus (HCoV-229E), the latter according to...
Jenniffer Cruz, Miguel Orlando Suárez-Barrera, Paola Rondón-Villarreal, Andrés Olarte-Diaz, Fanny Guzmán, Lydia Visser, Nohora Juliana Rueda-Forero
Genetic Modification Approaches for Parasporins Bacillus thuringiensis Proteins with Anticancer Activity
Published in: Molecules
Bacillus thuringiensis (Bt) is a bacterium capable of producing Cry toxins, which are recognized for their bio-controlling actions against insects. However, a few Bt strains encode proteins lacking insecticidal activity but showing cytotoxic activity against different cancer cell lines and low or no cytotoxicity toward normal human cells. A subset of Cry anticancer proteins, termed parasporins (PSs), has recently arisen as a potential alternative for cancer treatment. However, the molecular receptors that allow the binding of PSs to cells and their cytotoxic mechanisms of action have not been...
Miguel O. Suarez-Barrera, Lydia Visser, Paola Rondon-Villarreal, Diego F. Herrera-Pineda, Juan S. Alarcon-Aldana, Anke van den Berg, Jahir Orozco, Efrain H. Pinzon-Reyes, Ernesto Moreno, Nohora J. Rueda-Forero